Publications by authors named "Teresa M Giret"

Current strategies in circulating tumor cell (CTC) isolation in pancreatic cancer heavily rely on the EpCAM and cytokeratin cell status. EpCAM is generally not considered a good marker given its transitory change during Epithelial to Mesenchymal Transition (EMT) or reverse EMT. There is a need to identify other surface markers to capture the complete repertoire of PDAC CTCs.

View Article and Find Full Text PDF
Article Synopsis
  • The study explores how combining radiotherapy and immune checkpoint inhibitors can boost tumor responses while examining the potential side effect of lung inflammation caused by these treatments.
  • Researchers tested this by using a mouse model with Lewis lung carcinoma, monitoring tumor response and lung inflammation through imaging and blood analysis.
  • The results identified specific imaging features that could predict lung inflammation, providing a foundation for developing models that help manage risks associated with this combined cancer therapy.
View Article and Find Full Text PDF

Purpose: Immunotherapy (IT) and radiotherapy (RT) can act synergistically, enhancing antitumor response beyond what either treatment can achieve separately. Anecdotal reports suggest that these results are in part due to the induction of an abscopal effect on non-irradiated lesions. Systematic data on incidence of the abscopal effect are scarce, while the existence and the identification of predictive signatures or this phenomenon are lacking.

View Article and Find Full Text PDF

Circulating tumor cells (CTCs) have been recognized as a major contributor to distant metastasis. Their unique role as metastatic seeds renders them a potential marker in the circulation for early cancer diagnosis and prognosis as well as monitoring of therapeutic response. In the past decade, researchers mainly focused on the development of isolation techniques for improving the recovery rate and purity of CTCs.

View Article and Find Full Text PDF

Unlabelled: There are currently 5 million to 10 million human T-lymphotropic virus type 1 (HTLV-1)-infected people, and many of them will develop severe complications resulting from this infection. A vaccine is urgently needed in areas where HTLV-1 is endemic. Many vaccines are best tested in nonhuman primate animal models.

View Article and Find Full Text PDF